Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

StatusWithdrawn
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Withdrawn Sponsor's reason: The study was terminated because the protocol was upgraded after being considered insufficiently advanced. Show 5 more changesShow less
    • Enrollment target: estimated 28 to confirmed 0
    • Primary completion moved earlier from Dec 1, 2026 to Mar 31, 2026
    • Study completion moved earlier from Jan 1, 2027 to Mar 31, 2026
    • Eligibility criteria expanded, about 19 words
    • Site details revised
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal carcinoma, the main purpose of which is to evaluate the efficacy of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal carcinoma.
Trial Details
NCT Number NCT05290194
Lead Sponsor Fifth Affiliated Hospital, Sun Yat-Sen University
Conditions
(from sponsor)		 Radiotherapy, PD-1 Inhibitor, Capecitabine, Nasopharyngeal Carcinoma
Related terms Nasopharyngeal Carcinoma
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov